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IMPACT OF VENTILATOR-ASSOCIATED PNEUMONIA ON 
RESOURCE UTILIZATION AND PATIENT OUTCOME 
Stephane Hugonnet, MD, MSc; Philippe Eggimann, MD; Francois Borst, MD; Patrice Maricot; Jean-Claude Chevrolet, MD; 
Didier Pittet, MD, MS 
ABSTRACT 
OBJECTIVE: To assess the effect of ventilator-associated 
pneumonia on resource utilization, morbidity, and mortality. 
DESIGN: Retrospective matched cohort study based on 
prospectively collected data. 
SETTING: Medical intensive care unit of a university 
teaching hospital. 
PATIENTS: Case-patients were all patients receiving 
mechanical ventilation for 48 hours or more who experienced an 
episode of ventilator-associated pneumonia. Control-patients 
were matched for number of discharge diagnoses, duration of 
mechanical support before the onset of pneumonia among case-
patients, age, admission diagnosis, gender, and study period. 
RESULTS: One hundred six cases of ventilator-associat-
ed pneumonia were identified in 452 patients receiving mechani-
cal ventilation. The matching procedure selected 97 pairs. Length 
of stay in the intensive care unit and duration of mechanical ven-
tilation were greater among case-patients by a mean of 7.2 days 
(P< .001) and 5.1 days (P< .001), respectively. Median costs were 
$24,727 (interquartile range, $18,348 to $39,703) among case-
patients and $17,438 (interquartile range, $12,261 to $24,226) 
among control-patients (P< .001). The attributable mortality rate 
was 7.3% (P = .26). The attributable extra hospital stay was 10 
days with an extra cost of $15,986 per episode of pneumonia. 
CONCLUSION: Ventilator-associated pneumonia nega-
tively affects patient outcome and represents a significant burden 
on intensive care unit and hospital resources (Infect Control Hosp 
Epidemiol 2004;25:1090-1096). 
Healthcare-associated infection is the leading pre-
ventable adverse event among hospitalized patients, 
affecting 2 million individuals and costing $10 to $20 bil-
lion every year in the United States.1'2 Critically ill patients 
represent a large part of this burden and pneumonia is 
known to be the leading infection in this population.3-4 
Ventilator-associated pneumonia (VAP) occurs in approxi-
mately 25% of patients receiving mechanical ventilation at 
a rate of 4 to 25 episodes per 1,000 ventilator-days5"10 and 
has a crude mortality rate ranging from 20% to 70%.1115 
The impact of VAP on mortality remains controver-
sial; some studies found that VAP had a significant excess 
mortality,312'1617 whereas others did not.14'15-1820 Although 
mortality is an important element that will help evaluate 
the impact of prevention efforts, it might not be the best 
outcome indicator because (1) attributable mortality 
might be marginal among patients receiving ventilation 
who are already extremely ill and at high risk of death and 
(2) it does not capture what happens in patients who sur-
vive an episode of VAP. Length of intensive care unit 
(ICU) or hospital stay has been shown to be greater 
among patients with VAP.1318'21 From a health economy 
perspective, extra costs generated by VAP are another 
important outcome and, to our knowledge, have not been 
adequately studied. The aim of this study was to investi-
gate outcomes attributable to VAP, with an emphasis on 
morbidity and costs. 
M E T H O D S 
Study Design 
The University of Geneva Hospitals healthcare 
delivery system includes medical, surgical, pediatric, and 
neonatal ICUs. The study was conducted in the 18-bed 
medical ICU, to which 1,400 patients are admitted per 
year for a mean stay of 4 days. We performed a retrospec-
tive matched (1:1) cohort study using prospectively col-
lected surveillance data from October 1995 to November 
1997 to compare all patients with VAP (case-patients) with 
an individually matched cohort of patients receiving 
mechanical ventilation without pneumonia (control-
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patients). Surveillance definitions, diagnostic procedures, 
and clinical management of patients with pneumonia did 
not change during the study period.22 Patients were dis-
charged from the ICU according to specific guidelines 
designed for this unit, and compliance with these was 
checked daily by a senior staff member. Discharge policy 
did not change during the study period. 
Surveillance and Definitions 
We conducted on-site prospective surveillance of all 
nosocomial infections.22 Briefly, one infection control 
nurse visited the ICU daily (5 days per week) and com-
pleted a dedicated surveillance chart for all patients who 
stayed in the unit for 48 hours or more. Surveillance was 
continued up to 5 days after ICU discharge to detect infec-
tions that were acquired in this setting, but clinically evi-
dent only after discharge.23 Nosocomial infections were 
defined according to Centers for Disease Control and 
Prevention criteria,22,24,25 except that asymptomatic bac-
teriuria was not considered an infection26 and the defini-
tion of pneumonia was modified as described below. 
Information was collected regarding all nosocomial 
infections, demographic characteristics, admission and 
discharge diagnoses, exposure to invasive devices, ICU 
and hospital survival status, and costs. 
Estimation of Costs 
The University of Geneva Hospitals has developed a 
system to compute patient costs to comply with Swiss legal 
requirements. The model is based on both hospital 
accounting data and patient activity data extracted from the 
hospital information system. A total cost for each hospital 
administrative structure (eg, ICU, radiology department, 
or microbiology laboratory) is first computed by adding 
internal costs of the structure itself and imported costs 
from other hospital structures. Unit costs are then comput-
ed for each resource produced by this structure by dividing 
the total cost by the sum of produced activity. These unit 
costs are finally redistributed to patients according to their 
consumed resources, thus providing a precise allocation of 
total hospital expenditures to real patient costs. As a final 
result, the sum of all patient costs is absolutely equal to the 
total hospital care expenditure. This model has been imple-
mented in another Swiss university hospital and has been 
validated by external auditing offices; it has now also been 
chosen for use in all Swiss hospitals. Costs were converted 
from Swiss francs into U.S. dollars using the exchange rate 
of the middle of the study period (ie, a factor of 1.3 Swiss 
franc for 1 U.S. dollar). 
Case-Patients 
VAP was defined according to modified Centers for 
Disease Control and Prevention criteria,24,25 which are 
close to those established by the American College of 
Chest Physicians27 and those adopted by the board of 
directors of the American Thoracic Society.28 VAP was 
diagnosed in a patient receiving mechanical ventilation for 
48 hours who presented a clinical suspicion requiring the 
presence of two of the following: fever (increase of & 1°C 
or body temperature > 38.3°C); leukocytosis (25% 
increase and a value & 10,000 mm3) or leukopenia (25% 
decrease and a value =s 5,000 mm3); or purulent tracheal 
secretions (> 25 neutrophils per high-powered field). The 
patient also had to have one of the following: new and per-
sistent infiltrates on chest radiograph (when available, 
positive cultures, the specimens for which had been 
obtained from bronchoalveolar lavage [& 104 colony-form-
ing units/mL], were taken into account to support the 
diagnosis); the same microorganism isolated from pleural 
fluid and tracheal secretions, radiographic cavitation, or 
histopathologic demonstration of pneumonia; or positive 
cultures, the specimens for which had been obtained from 
bronchoalveolar lavage. Only the first episode of VAP was 
considered. 
Selection of Control-Patients 
A control-patient was a patient as similar as possible 
to a case-patient, but without VAP.29,30 Eligible control-
patients were all patients who benefited from mechanical 
ventilation for 48 hours or more and who remained free of 
pneumonia during their entire ICU stay. Case-patients 
were individually matched with one control-patient on sev-
eral variables, and a 20-point scale scoring system was 
determined to ensure optimal matching as follows: total 
number of discharge diagnoses30,31 ± 2 (6 points); duration 
of mechanical ventilation of the control-patient at least 
that of the case-patient until pneumonia occurred minus 
10% (5 points); age + 5 years (4 points) or ± 6 to 10 years 
(3 points); ICU admission diagnosis according to 
International Classification of Diseases, 10th edition (3 
points); gender (1 point); and study period (admission 
before or after March 1,1997) (1 point). All possible pairs 
were investigated and the best control-patient for each 
case-patient was retained. If several control-patients had 
the same score when matched for a particular case-
patient, one was randomly selected. If a control-patient 
was the best for more than one case-patient, then the sec-
ond best on the list was selected, and this procedure was 
repeated until each control-patient was used only once. 
Based on an a priori decision, only pairs with a score of 
15/20 or greater were kept for analysis. 
Statistical Analysis 
The main measures of interest were the ICU length 
of stay, duration of mechanical ventilation, costs, and mor-
tality rate. Secondary measures were hospital length of 
stay, costs, and mortality rate. 
Length of stay, duration of mechanical ventilation, 
and costs were compared among the entire cohort and 
among pairs in which both the case-patient and the con-
trol-patient survived.30 
Continuous variables were expressed as medians 
and ranges or interquartile ranges. To respect the match-
ing,32 attributable length of stay, duration of mechanical 
ventilation, and costs were expressed as the means of the 
individual case-control differences. Significance tests 
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TABLE 1 
LENGTH OF STAY AND COSTS ACCORDING TO INFECTION STATUS FOR THE MEDICAL INTENSIVE CARE UNIT, UNIVERSITY OF GENEVA 
HOSPITALS, 1995 TO 1997* 
No. Median Length of Stay (d) Median Costs (U.S. Dollars) 
Total study population 1,068 
Patients without ICU-acquired infection 787 
Patients with ICU-acquired infection 281 
Patients with ICU-acquired VAP 106 
5 (3-9) 
4 (2-6) 
11 (8-18) 
16 (11-25) 
8,228 (5,409-14,351) 
6,691 (4,767-9,759) 
19,032 (12,759-28,561) 
26,597 (18,662-40,756) 
ICU = intensive care unit; VAP = ventilator-associated pneumonia. 
'Interquartile ranges appear in parentheses. 
were performed using the one-sample Student's t test, and 
95% confidence intervals (CI%) based on the t distribution 
were reported. 
The attributable mortality rate of VAP was the dif-
ference in case-fatality rate between case-patients and 
control-patients. We used the McNemar method to test 
whether the attributable mortality rate differed from zero 
and built confidence intervals using the normal approxi-
mation of the binomial distribution. 
All tests were two-tailed, and P values of .05 or less 
were considered statistically significant. All statistical 
analyses were conducted with STATA software (version 
6.0; STATA Corp., College Station, TX). 
RESULTS 
Total Surveyed Population 
During the study period, we surveyed 1,049 
patients admitted to the medical ICU for 48 hours or 
more, accounting for 1,068 patient-stays. The median age 
was 63 years (range, 16 to 92 years), and the male-to-
female ratio was 1:4. The median ICU stay was 5 days 
(range, 2 to 134 days). Device use was as follows: 88% of 
patients had a peripheral catheter, 67% had a central 
catheter, 83% had an arterial catheter, 70% had a urinary 
catheter, and 42% underwent mechanical ventilation. We 
detected 554 ICU-acquired infections in 281 patients 
(26.8%). Leading infections were pneumonia (28.7%), 
bloodstream (20.4%), skin and soft tissue (15.3%), catheter 
exit site (13.5%), and urinary tract (11.2%). Compared with 
patients without ICU-acquired infection, patients with any 
type of ICU-acquired infection and patients with VAP had 
a median length of stay and costs that were almost 3 times 
greater and 4 times greater, respectively (Table 1). 
ICU and hospital mortality rates were 16.8% and 
24.4%, respectively. Most ICU deaths occurred among 
patients receiving mechanical ventilation (140 [31.0%] of 
452 patients receiving ventilation vs 39 [6.3%] of 616 
patients not receiving ventilation, yielding a relative risk 
of death of 4.9 [CI%, 3.5 to 6.8]). 
Overall, 452 patients benefited from mechanical 
ventilation. Among these, 11 were excluded because the 
episode of pneumonia occurred before or within 48 hours 
of the start of ventilatory support. Of 441 patients receiv-
ing mechanical ventilation, 106 (24%) developed VAP, 
resulting in an infection rate of 37.0 per 1,000 ventilation-
days (CI95, 30.6 to 44.9). 
Success of Matching 
The cohort of eligible control-patients consisted of 
335 patients who were matched with 106 case-patients. 
Nine pairs (8.5%) were excluded due to insufficient match-
ing, leaving 97 pairs for further analysis. All pairs were 
matched for the number of discharge diagnoses, 92% for 
the duration of mechanical ventilation before the onset of 
VAP in case-patients, 73% for age ± 5 years, 92% for age + 
10 years, 85% for admission diagnosis, 85% for study peri-
od, and 71% for gender. Although pulmonary disease as an 
admission diagnosis was more frequent among case-
patients, this trend did not reach statistical significance 
(P = .13). The median score was 19 points (range, 15 to 20 
points); 26 pairs were perfectly matched. Eighty-seven 
percent of the variables (508 of 582) were successfully 
matched. 
Of 97 episodes of VAP, 69 (71%) were diagnosed 
through quantitative or semiquantitative culture tech-
niques. Seventeen episodes were polymicrobial. The lead-
ing pathogens were gram-negative microorganisms (54%), 
mainly Pseudomonas aeruginosa (12%), Enterobacter 
species (9%), Haemophilus influenzae (7%), and Escherichia 
coli (6%). Staphylococcus aureus accounted for 10% of the 
pathogens identified. 
Case-patients and control-patients did not differ in 
terms of the matching variables and nosocomial infec-
tions, other than VAP (Table 2). Hospital stay before ICU 
admission and ICU stay before initiation of mechanical 
ventilation were similar in the two groups. The total dura-
tion of mechanical ventilation was significantly greater 
among the case-patients. 
In Table 2, control-patients selected by the match-
ing process are compared with the remaining eligible con-
trol-patients. Illness tended to be more severe among 
selected control-patients as the number of discharge diag-
noses, duration of mechanical ventilation, ICU stay, and 
proportion of other ICU-acquired infections were all 
greater. The median ICU length of stay was 10 days 
(interquartile range, 7 to 14 days) and 4 days (interquar-
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TABLE 2 
SELECTED CHARACTERISTICS OF THE STUDY POPULATION FROM THE MEDICAL INTENSIVE CARE UNIT, UNIVERSITY OE GENEVA HOSPITALS, 
1995 TO 1997* 
Characteristic 
Matching variables 
No. of discharge diagnoses 
No. of ventilation-days at risk 
Age, y 
Admission diagnosis, no. (96) 
Cardiovascular disease 
Infectious disease 
Pulmonary disease 
Other disease 
Period, no. (%) 
Before March 1, 1997 
After March 1, 1997 
Gender, no. (%) 
Male 
Female 
Other variables 
Hospital stay before ICU admission, d 
ICU stay before mechanical ventilation, d 
Total duration of mechanical ventilation, d 
ICU-acquired infections, no. (%) 
Primary bloodstream infection 
Catheter exit-site infection 
Urinary tract infection 
Other nosocomial infection 
Any nosocomial infection other than VAP 
Case-Patients 
(N = 97) 
6 (4-8) 
7 (4-9) 
65.6 (55.3-72.2) 
19 (19.6) 
49 (50.5) 
16 (16.5) 
13 (13.4) 
67 (69.1) 
30 (31.0) 
63 (65.0) 
34 (35.0) 
0 (0-1) 
0(0-1) 
10 (6-16) 
23 (23.7) 
9 (9.3) 
14 (14.4) 
35 (36.1) 
55 (56.7) 
Selected Control-
Patients (N = 97) 
6(5-8) 
7 (4-10) 
63.1 (51.6-71.3) 
17 (17.5) 
57 (58.8) 
11 (11.3) 
12 (12.4) 
66 (68.0) 
31 (32.0) 
57 (58.8) 
40 (41.2) 
0(0-1) 
0(0-0) 
7 (4-10) 
29 (29.9) 
14 (14.4) 
10 (10.3) 
24 (24.7) 
47 (48.5) 
P> 
.38 
.43 
.22 
.08 
1.00 
.34 
.27 
.49 
<.001 
.38 
.36 
.48 
.098 
.24 
Eligible Control-
Patients (N = 
5 (3-6) 
2 (1-3) 
238) 
59.3 (41.4-72.7) 
34 (14.3) 
101 (42.4) 
24 (10.1) 
79 (33.2) 
158 (66.4) 
80 (33.6) 
128 (53.8) 
110 (46.2) 
0(0-1) 
0(0-0) 
2 (1-3) 
14 (5.9) 
6 (2.5) 
8 (3.4) 
14 (5.9) 
37 (15.6) 
r* 
<.001 
<,001 
.23 
.001 
.77 
.41 
.59 
.015 
<.001 
<.001 
<.001 
.011 
<.001 
<.001 
ICU - intensive care unit; VAP = ventilator-associated pneumonia. 
*Continuous variables are summarized as medians (interquartile ranges). All P values are two-tailed. 
fP values are for the comparison between case-patients and selected control-patients. 
lvalues are for the comparison between selected control-patients and eligible control-patients. 
tile range, 3 to 6 days) among control-patients and 
non-selected control-patients, respectively (P< .001). 
Invasive Devices and Antibiotics 
The median duration of exposure among control-
patients and case-patients before the onset of VAP was 9 
and 7 days for central venous catheters (P = .059), 8 and 8 
days for arterial catheters (P = .30), 8 and 7 days for urinary 
catheters {P = .50), and 8 and 7 days for antibiotics (P= .01), 
respectively. When the same exposures were compared 
between control-patients and case-patients during the 
entire ICU stay, all were greater among case-patients: 9 and 
14 days for central venous catheters, 8 and 13 days for arte-
rial catheters, 8 and 13 for urinary catheters, and 8 and 13 
for antibiotics, respectively (all P values < .001). 
ICU Length of Stay, Costs, and Mortality 
ICU length of stay and duration of mechanical ven-
tilation were significantly greater among case-patients 
(Table 3). 
The median costs were $20,941 (interquartile 
range, $15,273 to $32,947) among the total population and 
were significantly higher among case-patients, resulting 
in mean attributable costs of $10,450 (CI%, $5,521 to 
$15,380) per episode of VAP (Table 3), totaling $1,107,700 
when considering all 106 episodes of VAP that occurred 
during the study period. The distribution of costs strati-
fied by infection status according to the main categories is 
shown in the figure. 
The ICU mortality rate was 28.4% (55 of 194). The 
case-fatality rate among case-patients and control-patients 
was 32.0% and 24.7%, respectively, resulting in an attribut-
able mortality rate of 7.3% (CI95, -6.4% to 20.8%) and a rela-
tive risk of death of 1.3 (CI95, 0.8 to 2.0). 
Hospital Length of Stay, Costs, and Mortality 
The median hospital length of stay among case-
patients and control-patients was 33.5 days (interquartile 
range, 18.5 to 59 days) and 23.5 days (interquartile range, 
15 to 43 days), respectively, yielding a mean attributable 
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TABLE 3 
LENGTH OF STAY IN THE INTENSIVE CARE UNIT, DURATION OF MECHANICAL VENTILATION, AND COSTS ATTRIBUTABLE TO VENTILATOR-
ASSOCIATED PNEUMONIA IN THE MEDICAL INTENSIVE CARE UNIT, UNIVERSITY OF GENEVA HOSPITALS, 1995 TO 1997* 
No. of Pairs Case-Patients* Control-Patients* Attributable to VAP* (CI9B) 
Length of stay, d 
Total population 
Survivors 
Duration of mechanical 
ventilation, d 
Total population 
Survivors 
Costs, U.S. dollars 
Total population 
Survivors 
97 
50 
97 
50 
96 
49 
15 (11-24) 
15.5 (10-24) 
10 (6-16) 
11 (6-17) 
24,727 (18,348-39,703) 
26,015 (18,428-37,315) 
10 (7-14) 
11 (8-14) 
7 (4-10) 
7.5 (4-10) 
17,438 (12,261-24,226) 
18,498 (13,900-24,755) 
7.2 (4.1-10.4) 
5.9 (2.8-9.1) 
5.1 (2.2-8.0) 
4.3 (1.5-7.1) 
10,450 (5,521-15,380) 
7,925 (1,563-14,287) 
VAP - ventilator-associated pneumonia; CI^ = 95% confidence interval. 
*Summary measures are medians (interquartile ranges). 
tSummary measures are means of the difference between case-patients and control-patients. 
FIGURE. Costs among patients with ventilator-associated pneumonia 
(cases), closely matched control-patients without pneumonia (controls), 
and patients who remained free of any intensive care unit-acquired infec-
tion (non-infected patients). Mean costs include costs of the ward (physi-
cians and nurses), laboratory, and imaging. Costs are total costs and 
include overheads. 
extra length of stay of 10.0 days (P = .06). Hospital costs 
among case-patients were higher than those among con-
trol-patients by a mean excess of $15,986. The in-hospital 
case-fatality rate was similar in case-patients and control-
patients (37.1 vs 38.1%; P = 1.00). 
D I S C U S S I O N 
Healthcare-associated infections in the ICU dramat-
ically affect morbidity and the use of hospital resources. 
Our study showed that patients with any nosocomial infec-
tion and those with VAP had an ICU stay that was 3 and 4 
times longer, respectively, than that of patients without 
nosocomial infection. Extra costs were also generated in 
the same proportions. 
Patients receiving mechanical ventilation represent 
a large proportion of ICU patients, more than 40% in the 
current study, which was similar to other reports.320,33 
They are at high risk of nosocomial pneumonia, as well as 
death, and we showed that most of the ICU deaths 
occurred in this group of patients. Investigating outcomes 
of VAP using a matched cohort study design makes case-
patients and control-patients relatively similar apart from 
the presence of VAP so that differences in terms of mor-
bidity, costs, and mortality can be attributed to the infec-
tion, provided that the selected matching variables ade-
quately control for confounding. We found that VAP was 
associated with a significant excess of ICU length of stay 
and costs and a trend toward a higher case-fatality rate. 
To our knowledge, 11 published matched cohort 
studies have investigated outcome attributable to 
VAP 13,16,18,21,34-40
 T w o a r e difficult to interpret because of 
insufficient matching38 or inclusion of nosocomial pneu-
monia other than VAP,37 and one was presented in abstract 
form only.39 
Length of stay is a recognized surrogate marker of 
patient morbidity. It provides a good estimate of the bur-
den on hospital resources, is not dependent on the 
accounting system or differences between countries, and 
is consequently widely used for comparison purposes. 
Whereas extra costs attributable to VAP estimate the 
direct economic loss, extra length of stay gives more 
insight into the impact of VAP on workload and loss of 
new admissions due to beds occupied by infected 
patients.31 We found that the mean ICU and hospital extra 
length of stay was 7.2 and 10.0 days, respectively. There is 
homogeneity of the results in most studies in the litera-
ture, as the median ICU extra stay ranged from 5 to 6 
days.13,16-21'34,36 Hospital extra stay is also consistent across 
studies, ranging from 9 to 11.5 days.13'182134 In our study, 
control-patients were tightly matched on the number of 
days of mechanical ventilation before the onset of pneu-
monia, making the estimate of the extra days of mechani-
cal ventilation of great value. Prolongation of mechanical 
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ventilation was 5.1 days, similar to results reported in 
other studies that used the same matching variables.13'2139 
Regardless of the matching procedure, case definition, 
patient profile, or microorganism involved, it appears 
clearly that VAP negatively affects patient morbidity. 
Consequently, we believe that there is enough evidence to 
support these findings and that the increased morbidity 
should be sufficient to stimulate prevention efforts.41,42 
At a time of cost containment, estimating the finan-
cial burden of nosocomial infection is a pivotal tool for 
infection control practitioners to compete for resources. 
However, cost estimation is not a straightforward exercise 
and some caveats may be difficult to avoid.31'4345 Because 
of cost shifting between items and departments, charges 
do not equal costs (charges are usually larger). Costs rep-
resent a more reliable estimate of the financial burden 
and should be preferred to charges.31 To our knowledge, 
only four studies with a similar design have estimated 
costs attributed to VAP. ICU extra costs per episode were 
obtained by multiplying the number of ICU extra days by 
the mean costs per day in the ICU and reached $8,80036 
and $7,750.21 With the use of hospital charges, extra costs 
reached $40,000 per episode in two other studies.1834 The 
methodology we used to assess the financial burden of 
VAP differs from those used by previous studies and can 
be considered as the gold standard.31'43'4647 First, our 
method is close to microcosting techniques, in which a 
complete list of all care items and services is used. This 
list allows for computing the total cost of each item and 
each patient, knowing the precise resource consumption 
of each patient. Our approach was possible due to the 
availability of online and daily updated data generated by 
the hospital information system.4849 Second, we used 
costs instead of charges, which are a more accurate mea-
sure, independent of cost shifting.31,43 We found that total 
hospital costs attributable to VAP were more than $15,000, 
with most of this amount being used while the patient was 
in the ICU. A recently published study found a similar fig-
ure, as the hospital cost attributed to VAP was estimated 
by multiple linear regression to be approximately 
$12,000.50 
The case-fatality rate among patients with VAP 
ranges from 23% to 70%,111316 but the extent to which VAP 
contributes to death remains controversial. Four matched 
cohort studies showed that VAP had a significant attribut-
able mortality rate, ranging from 13.5% to 27.1%,16,35,39'40 
but four others failed to demonstrate such an 
effect.13,18,21,34 In the current study, the case-fatality rate 
among case-patients was 32.0% and the attributable mor-
tality rate was 7.3%. A reason why we were unable to show 
a significant difference in mortality may relate to the fact 
that matching on surrogates of severity of illness may 
have correctly controlled for the severity bias that falsely 
attributed ICU mortality to VAP in several of the previous 
studies. Another reason may be that our study was under-
powered to detect a difference, which was the case with 
all of these studies except one.18 
Our study has some limitations. We used surveil-
lance definitions that include both clinical signs and symp-
toms and results of invasive diagnostic procedures to 
define VAP, which is neither sensitive nor specific.51,52 
Minei et al. illustrated, in a cohort of surgical ICU 
patients, that different definitions of VAP greatly affected 
the infection rate, showed little concordance between 
them, and identified different patients and, consequently, 
that risk factors for meeting one definition or the other 
were different.53 Predicting the direction of the bias 
resulting from this misclassification would be hazardous; 
however, the use of invasive diagnostic procedures did 
not add a prognostic value to the suspicion of VAP based 
on clinical criteria.54 Clearly, all studies dealing with VAP 
are to some extent limited by the issue of the case defini-
tion, and this calls for further research. 
The best estimate of the attributable outcome 
requires that the matching process remove the effect of 
confounding factors. However, the ideal matching vari-
ables are a subject of debate, raising the issue of insuffi-
cient matching or over-matching. Unlike several matched 
cohort studies,13,16,18,21,40 our study did not match on a 
severity score such as the Acute Physiology and Chronic 
Health Evaluation, but achieved a close match on the 
number of days of mechanical ventilation before the onset 
of VAP and the number of discharge diagnoses, as sug-
gested by Haley.31 Matching on a severity score recorded 
at admission poses two problems. First, it predicts mor-
tality and may thus result in over-matching. Second, it 
does not take into account what happens between admis-
sion and onset of VAP. Matching on the number of venti-
lation-days provides a more dynamic measure and 
accounts for changes in the patient's condition over time. 
Haley showed that the number of discharge diagnoses 
was a true confounder because it was associated with both 
nosocomial infections and length of stay and costs31 and 
that it can be used to account for severity of illness. 
Selected control-patients were extremely ill, more ill than 
the eligible control-patients who were finally not selected, 
and probably just as ill as the case-patients before the 
onset of VAP (Table 2). Furthermore, close matching also 
ensured that case-patients and control-patients experi-
enced the same frequency of primary bloodstream infec-
tion, which is associated with high mortality and morbidi-
ty.30 Therefore, our matching procedure met its objective 
to render case-patients and control-patients as similar as 
possible apart from the presence of VAP. 
Infections acquired in the ICU account for a dispro-
portional high consumption of resources and negatively 
affect patient morbidity. In particular, the significant bur-
den of VAP justifies the implementation of specific pre-
ventive strategies and the need for further research with 
the ultimate objective of improving patient safety. 
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